Tsai W L, Cheng J S, Lai K H, Lin C P, Lo G H, Hsu P I, Yu H C, Lin C K, Chan H H, Chen W C, Chen T A, Li W L, Liang H L
Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Aliment Pharmacol Ther. 2008 Aug 1;28(3):304-11. doi: 10.1111/j.1365-2036.2008.03702.x.
The long-term outcome of percutaneous acetic acid injection (PAI) and percutaneous ethanol injection (PEI) for treating small hepatocellular carcinoma (HCC) remains unclear.
To compare the long-term outcome of PAI vs. PEI for treating small HCC.
From July 1998 to July 2004, 125 patients with small HCC were enrolled. Seventy patients receiving PAI and 55 patients receiving PEI were enrolled. There were no significant differences in the clinical characteristics between the two groups. Tumour recurrence and survival rates were assessed.
Mean follow-up time was 43 months. The local recurrence rate and new tumour recurrence rate were similar between the PAI and PEI groups. The PAI group had significantly better survival than the PEI group (P = 0.027). Multivariate analysis revealed that PAI was the significant factor associated with overall survival [PAI vs. PEI, RR: 0.639, 95% CI: (0.419-1.975), P = 0.038]. The treatment sessions required to achieve complete tumour necrosis were significantly fewer in the PAI group than in the PEI group (2.4 +/- 1.0 vs. 2.9 +/- 1.3, P = 0.018).
Percutaneous acetic acid injection required fewer treatment sessions than PEI and provided better survival after long-term follow-up.
经皮乙酸注射（PAI）和经皮乙醇注射（PEI）治疗小肝细胞癌（HCC）的长期疗效尚不清楚。
比较PAI和PEI治疗小HCC的长期疗效。
1998年7月至2004年7月，纳入125例小HCC患者。其中70例接受PAI治疗，55例接受PEI治疗。两组患者的临床特征无显著差异。评估肿瘤复发率和生存率。
平均随访时间为43个月。PAI组和PEI组的局部复发率和新肿瘤复发率相似。PAI组的生存率明显高于PEI组（P = 0.027）。多变量分析显示，PAI是与总生存率相关的显著因素[PAI与PEI相比，RR：0.639，95%CI：（0.419 - 1.975），P = 0.038]。PAI组实现肿瘤完全坏死所需的治疗次数明显少于PEI组（2.4±1.0对2.9±1.3，P = 0.018）。
经皮乙酸注射比PEI所需的治疗次数少，长期随访后生存率更高。
